Liquid oral components

Abstract

This invention provides a liquid oral composition with excellent retention properties for dodecylpyridinium chloride. [Solution] The liquid oral composition contains dodecylpyridinium chloride and a compound having a hydroxyl group.

Description

Technical Field

[0001] The present disclosure relates to liquid oral compositions and the like. The contents of all documents described in this specification are incorporated herein by reference.

Background Art

[0002] Fusobacterium is known as a bacterium related to periodontal disease. Fusobacterium is a mediator bacterium that is greatly involved in the plaque formation process. Through this mediator bacterium, late colonizing bacteria such as Porphyromonas gingivalis and Treponema denticola, which are anaerobic bacteria, adhere and aggregate, and the plaque matures. In particular, late colonizing bacteria are considered to cause periodontal disease and are directly or indirectly related to the destruction of periodontal tissues.

[0003] Also, Patent Document 1 shows that dodecylpyridinium chloride, which is C12 alkylpyridinium chloride, has an excellent bactericidal effect against Fusobacterium alone. However, dodecylpyridinium chloride has a problem of low retention in the oral cavity and low persistence of the effect. [[ID=I8]]

Prior Art Documents

Patent Documents

[0004]

Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0005] Effectively sterilizing Fusobacterium, which is a mediator bacterium at the previous stage, so as not to allow late colonizing bacteria that cause periodontal disease to adhere and aggregate is considered to lead to the prevention of periodontal disease as a result.

[0006] Therefore, studies were conducted on a preparation in which dodecylpyridinium chloride effectively stays in the oral cavity.

Means for Solving the Problems

[0007] In light of the current situation, the inventors conducted diligent studies and found that incorporating compounds having hydroxyl groups, such as thymol, terpioneol, isopropylmethylphenol, and geraniol, can improve the retention of dodecylpyridinium chloride in the oral cavity, thus completing the present invention.

[0008] In other words, the present invention encompasses the following inventions. Section 1. A liquid oral composition containing dodecylpyridinium chloride and one or more compounds having a hydroxyl group. Section 2. The liquid oral composition according to claim 1, wherein the content of dodecylpyridinium chloride is 0.01 to 0.5% by mass. Section 3. The liquid oral composition according to claim 1, wherein the compound having a hydroxyl group is one or more selected from the group consisting of thymol, terpineol, isopropylmethylphenol, geraniol, 1-hexanol, 1-octanol, 1-decanol, 2-methyl-2,4-pentanediol, and 2-ethyl-1,3-hexanediol. Section 4. The liquid oral composition according to claim 3, wherein the content of the compound having a hydroxyl group is 0.01 to 5% by mass. [Effects of the Invention]

[0009] The present invention improves the retention of dodecylpyridinium chloride (hereinafter also referred to as "DPC") in the oral cavity. This provides a method for efficiently killing Fusobacterium, a bacterium that mediates plaque formation, thereby suppressing plaque formation and preventing periodontal disease. [Modes for carrying out the invention]

[0010] The embodiments of the present invention will be described in further detail below.

[0011] The oral composition according to the present invention is characterized by containing one or more compounds having hydroxyl groups and dodecylpyridinium chloride.

[0012] <dpc> DPC is a quaternary ammonium compound and is used as a cationic disinfectant. There are no particular restrictions on the type of DPC; known DPCs can be used.

[0013] The DPC content in the liquid oral composition of this disclosure is not particularly limited as long as the effect is achieved, but for example, it is about 0.01 to 0.5% by mass. The upper or lower limits of this range are, for example, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.21, 0.22, 0.23, 0.24, The mass percentage may be 0.25, 0.26, 0.27, 0.28, 0.29, 0.3, 0.31, 32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38, 0.39, 0.4, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48, or 0.49%. For example, the range may be approximately 0.02 to 0.3% by mass, or approximately 0.03 to 0.1% by mass.

[0014] Examples of hydroxyl group-containing compounds used in the present invention include thymol (2-isopropyl-5-methylphenol), isopropylmethylphenol (4-isopropyl-3-methylphenol), terpineol, eugenol, linalool, geraniol, citronellol, 1-hexanol, 1-octanol, 1-decanol, 2-methyl-2,4-pentanediol, 2-ethyl-1,3-hexanediol, and 3-methyl-1,3-heptanediol. Of these, terpineol, isopropylmethylphenol, geraniol, 1-hexanol, 1-octanol, 1-decanol, 2-methyl-2,4-pentanediol, and 2-ethyl-1,3-hexanediol are preferred. More preferably, thymol, terpineol, isopropylmethylphenol, and geraniol are preferred as hydroxyl group-containing compounds used in the present invention. These can be used individually or in combination of two or more. The lower limit of the amount blended is preferably 0.01% by mass. The upper limit of the blending amount is preferably 5% by mass, more preferably 4% by mass, and even more preferably 3% by mass.

[0015] The liquid oral composition of the present invention may contain other components besides those described above, as long as they do not impair the effects of the present invention. Examples of other components include surfactants, flavoring agents, sweeteners, humectants, binders, preservatives, colorants, pH adjusters, chelating agents, pharmaceutically active ingredients, bases, abrasives, and the like. Other components that are known to be incorporated into liquid oral compositions may be used. The liquid oral composition may contain only one of the above-mentioned other components alone, or it may contain two or more in combination.

[0016] For example, nonionic surfactants, anionic surfactants, or amphoteric surfactants can be incorporated as surfactants. Specifically, examples of nonionic surfactants include sugar fatty acid esters such as sucrose fatty acid esters, maltose fatty acid esters, and lactose fatty acid esters; fatty acid alkanolamides; sorbitan fatty acid esters; fatty acid monoglycerides; polyoxyethylene alkyl ethers with a polyoxyethylene addition coefficient of 8 to 10 and 13 to 15 carbon atoms in the alkyl group; polyoxyethylene alkylphenyl ethers with a polyoxyethylene addition coefficient of 10 to 18 and 9 carbon atoms in the alkyl group; diethyl sebacate; polyoxyethylene hydrogenated castor oil; and fatty acid polyoxyethylene sorbitan. Examples of anionic surfactants include sulfate ester salts such as sodium lauryl sulfate and sodium polyoxyethylene lauryl ether sulfate; sulfosuccinates such as sodium lauryl sulfosuccinate and sodium polyoxyethylene lauryl ether sulfosuccinate; acyl amino acid salts such as sodium cocoyl sarcosinate and sodium lauroyl methylalanine; and sodium cocoyl methyl taurate. Examples of amphoteric surfactants include betaine-type surfactants such as lauryldimethylaminoacetic acid betaine and coconut oil fatty acid amidopropyldimethylaminoacetic acid betaine; imidazoline-type surfactants such as N-cocoyl-N-carboxymethyl-N-hydroxyethylethylenediamine sodium; and amino acid-type surfactants such as N-lauryldiaminoethylglycine. These surfactants can be used individually or in combination of two or more. The amount used is usually about 0.1 to 5% by mass of the total composition.

[0017] As fragrance agents, for example, menthol, carboxylic acid, anethole, eugenol, methyl salicylate, limonene, ocimene, n-decyl alcohol, citronellal, α-terpineol, methyl acetate, citronellyl acetate, methyl eugenol, cineol, ethyl linalool, spearmint oil, peppermint oil, lemon oil, orange oil, sage oil, rosemary oil, galbanum oil, perilla oil, wintergreen oil, clove oil, eucalyptus oil, pimento oil, d-camphor, d-borneol, star anise oil, cinnamon oil, cinnamon aldehyde, mint oil, vanillin and other fragrances can be used. These can be blended alone or in combination of two or more. The blending amount can be, for example, about 0.001 to 1.5% by mass based on the total amount of the composition.

[0018] As sweeteners, for example, sodium saccharin, acesulfame potassium, stevioside, neohesperidin dihydrochalcone, perillartine, thaumatin, aspartylphenylalanyl methyl ester, p-methoxycinnamic aldehyde and the like can be used. These can be blended alone or in combination of two or more. The blending amount can be, for example, about 0.01 to 1% by mass based on the total amount of the composition.

[0019] As wetting agents, sorbitol, ethylene glycol, propylene glycol, glycerin, 1,3-butylene glycol, polypropylene glycol, xylitol, maltitol, lactitol, polyoxyethylene glycol and the like can be blended alone or in combination of two or more.

[0020] As preservatives, parabens such as methyl paraben, ethyl paraben, propyl paraben, butyl paraben, sodium benzoate, phenoxyethanol, alkyldiaminoethyl glycine hydrochloride and the like can be blended. These can be blended alone or in combination of two or more.

[0021] As colorants, synthetic pigments such as Brilliant Blue No. 1, Tartrazine, Pigment Red No. 202, and Fast Green FCF, mineral pigments such as ultramarine, reinforced ultramarine, and navy blue, and titanium oxide may be blended. These can be blended alone or in combination of two or more.

[0022] As pH adjusters, citric acid, phosphoric acid, malic acid, pyrophosphoric acid, lactic acid, tartaric acid, glycerophosphoric acid, acetic acid, nitric acid, or chemically possible salts thereof, sodium hydroxide, etc. may be blended. These can be blended alone or in combination of two or more so that the pH of the composition is in the range of 4 to 8, preferably 5 to 7. The blending amount of the pH adjuster may be, for example, about 0.01 to 2% by weight.

[0023] In the liquid oral composition of the present disclosure, further, as medicinal ingredients, vitamin Es such as dl-α-tocopherol acetate, tocopherol succinate, or tocopherol nicotinate, amphoteric bactericides such as dodecyldiaminoethyl glycine, nonionic bactericides such as triclosan and hinokitiol, anionic bactericides such as sodium lauroyl sarcosinate, cationic bactericides such as chlorhexidine hydrochloride and benzethonium chloride, enzymes such as dextranase, amylase, protease, mutanase, lysozyme, and lysing enzyme (lytech enzyme), alkali metal monofluorophosphates such as sodium monofluorophosphate and potassium monofluorophosphate, fluorides such as sodium fluoride and stannous fluoride, tranexamic acid and epsilon-aminocaproic acid, aluminum chlorhydroxyl allantoin, dihydrocholesterol, glycyrrhetinic acid, glycyrrhizic acid, sodium copper chlorophyllin, glycerophosphate, chlorophyll, sodium chloride, caropeptide, allantoin, carbazochrom, hinokitiol, potassium nitrate, paratinit, etc. can be blended alone or in combination of two or more.

[0024] Alcohols, silicones, apatite, white petrolatum, paraffin, liquid paraffin, microcrystalline wax, squalane, Plastibase, etc., can also be added as bases. These can be used individually or in combination of two or more.

[0025] Specific examples of chelating agents include disodium edetate, phytic acid, pyrophosphate, polyphosphate, and malic acid. These chelating agents can be used individually or in combination of two or more.

[0026] The application forms of the liquid oral composition of the present invention are not particularly limited, and it can be used, for example, as a pharmaceutical product, a designated quasi-drug, a quasi-drug, or a cosmetic product. [Examples]

[0027] The present invention will be described in more detail below with reference to test examples and formulation examples, but the present invention is not limited to these. The oral compositions of Examples 1 to 12 and Comparative Example 1 were prepared according to conventional methods, with the compositions and content (mass%) shown in Tables 1 and 2 below.

[0028] [Table 1]

[0029] [Table 2]

[0030] (Evaluation test) The retention of DPC on tooth surfaces was evaluated for the liquid oral compositions of Examples 1 to 12 and Comparative Example 1 (hereinafter also referred to as "subjects"). The evaluation method and results are shown below.

[0031] (Method for evaluating DPC retention) The following procedure was used to prepare pretreated hydroxyapatite (hereinafter also referred to as HAP carrier) and to perform adsorption tests.

[0032] [Preparation of pretreatment solution] Bovine serum albumin (SIGMA-ALDRICH) was added to Dulbecco's Phosphate Buffered Saline (SIGMA-ALDRICH) to a concentration of 0.3% by mass. The mixture was stirred with a touch mixer until completely dissolved to prepare the pretreatment solution. This pretreatment solution was refrigerated until it was ready for testing.

[0033] [Preparation of HAP carriers] A HAP carrier exhibiting similar behavior to that of a tooth surface was prepared according to the following procedure. 50 mg of hydroxyapatite powder (Bio-Gel HTP Gel; manufactured by BIO-RAD Lab.) was weighed into a PP tube (Falcon2059). 2 mL of the above pretreatment solution was added to this hydroxyapatite powder, and after homogenization with a touch mixer, it was shaken in a constant temperature chamber set at 37°C for approximately 15 hours. Subsequently, centrifugation was performed again at room temperature, 3000 rpm, for 5 minutes, and the supernatant was removed to obtain the HAP support.

[0034] [Adsorption test] Approximately 50 mg of the HAP carrier obtained above was weighed, and 2 mL of each subject was added. After homogenization with a touch mixer, the mixture was shaken for 15 minutes in a constant temperature chamber set to 37°C. Subsequently, the supernatant was removed by centrifugation at room temperature, 3000 rpm, and 5 minutes. 2 mL of distilled water was added to the obtained residue. After homogenization with a touch mixer, the supernatant was removed by centrifugation at room temperature, 3000 rpm, and 5 minutes. The obtained residue was washed with distilled water under the same conditions as above, and the HAP carrier after adsorption treatment was obtained as the residue.

[0035] [Measurement of adsorption amount] To the HAP carrier obtained after the adsorption treatment described above, 5 mL of extraction solvent (a solution of 2.88 g of sodium lauryl sulfate dissolved in 1 L of 0.02 M citrate buffer at pH 3:acetonitrile = 1:3) was added to extract the DPC adsorbed on the HAP carrier. The amount of DPC adsorbed onto 50 mg of HAP carrier was determined using a known quantitative method with liquid chromatography. The same test was performed three times to determine the average adsorbed amount of DPC.

[0036] [Evaluation of DPC adsorption amount] Based on the calculated average DPC adsorption amount, the DPC adsorption amount was evaluated on a three-point scale (◎, ○, ×) and recorded in Table 1 or Table 2.

[0037] As described in Table 1 or Table 2, liquid oral compositions containing dodecylpyridinium chloride and one or more compounds having hydroxyl groups selected from the group consisting of thymol, terpineol, isopropylmethylphenol, geraniol, 1-hexanol, 1-octanol, 1-decanol, 2-methyl-2,4-pentanediol, and 2-ethyl-1,3-hexanediol showed a remarkable adsorption effect of dodecylpyridinium chloride on the hydroxyapatite surface.< / dpc>

Claims

1. A liquid oral composition comprising dodecylpyridinium chloride and one or more compounds having hydroxyl groups.

2. The liquid oral composition according to claim 1, wherein the content of dodecylpyridinium chloride is 0.01 to 0.5% by mass.

3. The liquid oral composition according to claim 1, wherein the compound having a hydroxyl group is one or two selected from the group consisting of thymol, terpineol, isopropylmethylphenol, geraniol, 1-hexanol, 1-octanol, 1-decanol, 2-methyl-2,4-pentanediol, and 2-ethyl-1,3-hexanediol.

4. The liquid oral composition according to claim 3, wherein the content of the compound having a hydroxyl group is 0.01 to 5% by mass.

Images